Cell-to-cell transmission of alpha-synuclein

Overview

flowchart TD
    experiments_extracellular_vesi["Cell-to-cell transmission of alpha-synuclein"]
    style experiments_extracellular_vesi fill:#4fc3f7,stroke:#333,color:#000
    experiments_extracel_0["Biological Rationale"]
    experiments_extracellular_vesi -->|"includes"| experiments_extracel_0
    style experiments_extracel_0 fill:#81c784,stroke:#333,color:#000
    experiments_extracel_1["EV Biology and Classification"]
    experiments_extracellular_vesi -->|"includes"| experiments_extracel_1
    style experiments_extracel_1 fill:#ef5350,stroke:#333,color:#000
    experiments_extracel_2["Prion-Like Propagation Mechanics"]
    experiments_extracellular_vesi -->|"includes"| experiments_extracel_2
    style experiments_extracel_2 fill:#ffd54f,stroke:#333,color:#000
    experiments_extracel_3["Experiment ID"]
    experiments_extracellular_vesi -->|"includes"| experiments_extracel_3
    style experiments_extracel_3 fill:#ce93d8,stroke:#333,color:#000
    experiments_extracel_4["Hypothesis to be Tested"]
    experiments_extracellular_vesi -->|"includes"| experiments_extracel_4
    style experiments_extracel_4 fill:#4fc3f7,stroke:#333,color:#000
    experiments_extracel_5["Primary Objectives"]
    experiments_extracellular_vesi -->|"includes"| experiments_extracel_5
    style experiments_extracel_5 fill:#81c784,stroke:#333,color:#000

Extracellular vesicles (EVs) have emerged as critical mediators of pathological alpha-synuclein propagation in Parkinson’s Disease and related synucleinopathies. This experiment investigates the hypothesis that EVs serve as the primary vehicle for intercellular transmission of disease-associated alpha-synuclein species, driving both the stereotypical progression of Lewy pathology throughout the nervous system and the release of detectable biomarkers into peripheral fluids.

The significance of EV-mediated synuclein propagation extends beyond basic biology to practical clinical applications. EVs are readily detectable in cerebrospinal fluid (CSF) and blood, offering a window into CNS pathology that has historically been inaccessible. Furthermore, the EV biogenesis pathway represents a potentially druggable target — interrupting either the loading of alpha-synuclein into EVs or the uptake of EV-associated synuclein by recipient cells could theoretically halt disease progression. This experiment therefore carries dual importance: understanding disease mechanism and identifying therapeutic intervention points.

Biological Rationale

EV Biology and Classification

Extracellular vesicles constitute a heterogeneous family of membrane-bound particles released by virtually all cell types. They are broadly classified into three categories based on their biogenesis: exosomes (30-150 nm, formed by invagination of the multivesicular body), microvesicles (100-1000 nm, shed directly from the plasma membrane), and apoptotic bodies (>1000 nm, released during programmed cell death). Each category carries a distinct cargo signature reflecting its cellular origin, and this cargo can include proteins, lipids, nucleic acids, and metabolites — essentially a snapshot of the originating cell’s interior.

For alpha-synuclein propagation, exosomes are thought to be particularly relevant due to their nanoscale size, abundance in CNS, and ability to cross biological barriers. The protein alpha-synuclein, despite being predominantly cytosolic, can be packaged into exosomes through mechanisms that remain incompletely understood but likely involve direct translocation across the limiting membrane of multivesicular bodies or sorting via interactions with lipid rafts and tetraspanin proteins (CD9, CD63, CD81). Notably, alpha-synuclein is enriched in exosomes derived from neurons and glial cells, and this enrichment is amplified in disease states.

Prion-Like Propagation Mechanics

The concept of prion-like propagation in neurodegenerative diseases emerged from observations that Lewy pathology spreads in a predictable temporal and spatial pattern through the brain. According to the Braak staging system, alpha-synuclein inclusions appear first in the lower brainstem and olfactory bulb (stages 1-2), then ascend to the midbrain and basal forebrain (stages 3-4), and ultimately reach the neocortex (stages 5-6). This pattern suggests a mechanism by which pathology propagates along neural connectivity rather than simply arising independently in vulnerable regions.

EVs provide a plausible biological substrate for this propagation. When a neuron containing pathological alpha-synuclein releases EVs, these particles can travel along axons, across synapses, or through the extracellular space to reach neighboring cells. Upon contact with a recipient neuron, EVs can deliver their cargo through multiple mechanisms: direct membrane fusion, receptor-mediated endocytosis, or clathrin-dependent uptake. Once inside the recipient cell, the delivered alpha-synuclein can template the conversion of endogenous soluble alpha-synuclein into the aggregated, phosphorylated form, thereby seeding a new focus of pathology.

This templating mechanism shares conceptual similarities with prion propagation but differs in important ways. Prion diseases involve a single protein that undergoes a profound conformational change; synucleinopathies involve multiple species (monomers, oligomers, fibrils) with varying degrees of pathogenicity. EV-mediated delivery may preferentially deliver oligomeric species, which many studies suggest are the most neurotoxic form.

See Also

• Mechanisms of Parkinson’s Disease Pathogenesis

• Alpha-Synuclein Aggregation Mechanisms

• Cell-to-Cell Propagation in Neurodegeneration

• Lewy Body Formation and Composition

• Biomarkers for Parkinson’s Disease

• Exosome Biology in Neurological Disease

External Links

• PubMed - Extracellular Vesicles and Alpha-Synuclein

• ClinicalTrials.gov - Parkinson’s Disease Biomarkers

Experiment ID

EV-SYN-PD-001

Hypothesis to be Tested

Primary Hypothesis: Extracellular vesicles (EVs) serve as the primary vehicle for pathological alpha-synuclein propagation in Parkinson’s Disease, contributing to both inter-neuronal spread and peripheral biomarker detectability.

Secondary Hypotheses:

• EV-associated alpha-synuclein species (particularly phosphorylated at Ser129 and oligomeric forms) are more sensitive and specific biomarkers than total alpha-synuclein for PD diagnosis

• Genetic risk factors for PD (mutations in GBA, LRRK2, SNCA) modify EV-synuclein cargo in ways that reflect disease biology

• Modulation of EV biogenesis or uptake can attenuate synuclein pathology in cellular and animal models

Primary Objectives

1. Quantify EV-associated alpha-synuclein in CSF and plasma from PD patients vs. healthy controls, stratified by disease stage and genetic status

2. Characterize EV cargo profiles in PD vs. controls using untargeted proteomics to identify disease-associated signatures beyond alpha-synuclein

3. Test EV transmission in cellular models of synuclein propagation, demonstrating intercellular transfer of pathology

4. Validate biomarkers for disease staging, progression monitoring, and differentiation from other synucleinopathies

Study Design

Phase 1: Clinical Biomarker Validation (Prospective Cohort Study)

Study Population:

• Parkinson’s disease patients (n=150): Newly diagnosed (≤2 years, Hoehn-Yahr 1), moderate (Hoehn-Yahr 2-3), advanced (Hoehn-Yahr 4-5)

• Healthy age-matched controls (n=75)

• Disease controls for specificity: Progressive supranuclear palsy (n=25), Multiple system atrophy (n=25), Dementia with Lewy bodies (n=25)

Sample Collection:

• CSF via lumbar puncture (collected in polypropylene tubes, centrifuged within 1 hour, aliquoted and frozen at -80°C)

• Blood plasma (EDTA tubes, processed within 2 hours, double-spun to remove cells and debris)

• Clinical assessment: MDS-UPDRS Parts I-III, Hoehn-Yahr staging, MoCA, University of Pennsylvania Smell Identification Test (UPSIT), REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ)

EV Isolation Protocols:

• CSF: Size-exclusion chromatography (qEV columns, Izon Science) followed by ultrafiltration concentration

• Plasma: Ultracentrifugation at 100,000 × g for 16 hours (modified protocol with floating lipoprotein removal)

• Characterization: Nanoparticle tracking analysis (NTA) for particle concentration and size distribution; Western blot for tetraspanin markers (CD9, CD63, CD81) and absence of cellular contaminants (calnexin, GM130)

Biochemical Assays:

• Alpha-synuclein total: ELISA (Thermo Fisher Human alpha-Synuclein Kit)

• Alpha-synuclein pSer129: ELISA (Fujirebio Phospho-Synuclein Kit)

• Alpha-synuclein oligomers: Single-molecule array (Simoa) with conformation-specific antibodies

• EV protein cargo: Label-free quantitative mass spectrometry (LC-MS/MS)

Phase 2: Mechanistic Studies (In Vitro)

Cell Models:

• iPSC-derived dopaminergic neurons from PD patients with GBA N370S or LRRK2 G2019S mutations, and from healthy controls

• SH-SY5Y cells engineered to express wild-type or mutant alpha-synuclein-YFP

• Primary rat cortical neurons for synaptic transmission studies

EV Characterization:

• Labeled EVs from patient-derived neurons (DiI membrane dye, PKH26)

• Transmission electron microscopy for morphology

• Cryo-electron microscopy for protein structure visualization

• Asymmetric flow field-flow fractionation for sub-population separation

Transmission Assays:

• Live cell imaging of fluorescently labeled EV uptake (confocal microscopy, 4-hour time course)

• Recipient cell pathology assessment: Thioflavin S aggregation, pSer129 immunohistochemistry, ProteoStat aggregation dye

• Transwell co-culture systems with physical separation to demonstrate cell-to-cell transmission

• Synaptic vesicle preparation for trans-synaptic EV transfer studies

Phase 3: Therapeutic Target Validation

Drug Repurposing Screen:

• FDA-approved drug library (Selleckchem, 2,800 compounds) for EV release inhibition

• Secondary validation of hits in primary neuron cultures

• Counter-screen for cytotoxicity

Mechanistic Compounds:

• EV release inhibitors: GW4869 (nSMase2 inhibitor), manumycin (Ras farnesyltransferase inhibitor)

• EV uptake inhibitors: Heparin, dynasore (dynamin inhibitor), cytochalasin D

• Alpha-synuclein aggregation modulators: NPT200-1, Anle138b, MBG-136

In Vivo Validation:

• Alpha-synuclein preformed fibril mouse model (C57BL/6J, bilateral striatal injection)

• EV modulation treatment arms (GW4869 IP daily, 10 mg/kg)

• Behavioral endpoints: Rotarod, cylinder test, gait analysis

• Pathological endpoints: pSer129 immunohistochemistry, stereological counting, biochemical analysis of striatum and cortex

Outcome Measures

Primary Endpoints

1. Diagnostic Sensitivity/Specificity: ROC curve analysis of CSF EV-associated pSer129 synuclein for PD vs. controls, with area under curve (AUC) as primary metric

2. Clinical Correlation: Spearman correlation between EV-synuclein levels and MDS-UPDRS motor scores, adjusting for disease duration

3. Mechanistic Proof: Demonstration of in vitro EV-mediated transmission of synuclein pathology from PD patient-derived neurons to naive cells, with biochemical confirmation

Secondary Endpoints

1. Disease Staging Biomarkers: EV-synuclein levels across Hoehn-Yahr stages, with pairwise comparisons

2. Cross-Biomarker Correlation: Correlation with CSF total tau, phosphorylated tau, and beta-amyloid42

3. Genetic Stratification: Comparison of EV cargo profiles across PD patients with different genetic risk factors (GBA, LRRK2, SNCA, sporadic)

4. Prognostic Value: Longitudinal EV biomarker changes over 24 months, correlated with clinical progression

Exploratory Endpoints

1. Proteomic profiling to identify novel EV cargo associated with PD

2. Metabolomic analysis of EV-associated small molecules

3. Transcriptomic analysis of recipient cells after EV exposure

Statistical Analysis

Sample Size Justification:

• Primary biomarker analysis: 80% power to detect 0.5 standard deviation difference in EV-synuclein levels between PD and controls, at α=0.05, requiring n=128 per group (adjusted to 150/75 for potential dropout)

Primary Analysis:

• Comparison of biomarker levels: Mann-Whitney U test (non-parametric, due to expected skewness)

• Diagnostic accuracy: ROC curve with DeLong method for confidence intervals

• Correlation analysis: Spearman rank correlation for clinical associations

Multiple Comparison Correction:

• Benjamini-Hochberg false discovery rate (FDR) for secondary endpoints, with q<0.10 threshold

• Bonferroni correction for biomarker panel comparisons

Multivariate Analysis:

• Logistic regression for diagnostic panel construction

• Mixed-effects models for longitudinal analysis, with random intercept for subject

Sensitivity Analyses:

• Exclude participants with concomitant neurodegenerative conditions

• Adjust for CSF blood contamination (xanthochromia, RBC count)

• Propensity score matching for age and sex

Ethical Considerations

• IRB approval required at all participating sites (multi-center study)

• Informed consent for all participants, including future use of samples

• Data safety monitoring board (DSMB) for Phase 3 therapeutic component

• Animal care in AAALAC-accredited facilities, IACUC approval

Budget Estimate

Timeline

• Months 1-6: Protocol finalization, IRB submissions, site initiation

• Months 7-18: Phase 1 cohort enrollment and sample collection

• Months 6-24: Phase 2 in vitro experiments (overlapping enrollment)

• Months 12-24: Phase 1 sample analysis

• Months 18-36: Phase 3 therapeutic validation

• Months 30-36: Final analysis and manuscript preparation

• Month 36: Primary analysis completion

Expected Impact

This comprehensive investigation of EV-mediated alpha-synuclein propagation is expected to yield several high-impact findings:

1. Validated Biomarker: Establish EV-associated pSer129 synuclein as a diagnostic biomarker for PD, potentially enabling earlier diagnosis and clinical trial enrichment

2. Mechanistic Insight: Provide direct evidence for EV-mediated intercellular transmission of synuclein pathology in human-derived cellular models

3. Therapeutic Targets: Identify the EV biogenesis pathway as a viable target for disease-modifying therapy, with validated compounds ready for translation

4. Disease Stratification: Characterize how genetic risk factors modify EV cargo, enabling precision medicine approaches in PD

Risk Mitigation